The Claim
Among Medicare Advantage beneficiaries with type 2 diabetes and obesity, initiating glucagon-like peptide-1 receptor agonists (GLP-1 RA) is associated with 2.9% lower medical costs over 12 months compared to initiating sodium-glucose cotransporter-2 inhibitors (SGLT2i), despite 9.5% higher pharmacy costs.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In Medicare Advantage patients with type 2 diabetes and obesity, starting GLP-1 RA drugs results in 2.9% lower overall medical costs over 12 months than starting SGLT2i drugs, even though GLP-1 RA drugs cost 9.5% more in pharmacy expenses.
See the scientific wording
Among Medicare Advantage beneficiaries with type 2 diabetes and obesity, initiating glucagon-like peptide-1 receptor agonists (GLP-1 RA) is associated with 2.9% lower medical costs over 12 months compared to initiating sodium-glucose cotransporter-2 inhibitors (SGLT2i), despite 9.5% higher pharmacy costs, suggesting a potential offset in non-pharmacy health care expenditures.
GLP-1 receptor agonists reduce fat tissue inflammation and improve how the body uses sugar and fat, which decreases stress on organs like the heart and kidneys. This leads to fewer hospital visits and doctor appointments, even though the medicine itself costs more.
What the research says
1 studyIn older adults with diabetes and obesity, starting a GLP-1 RA drug led to slightly lower doctor and hospital bills over a year than starting an SGLT2i drug—even though the GLP-1 RA pill cost more—because it may have reduced other medical needs.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.